These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26954717)

  • 1. Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
    Byrne NM; Nesbitt H; Ming L; McKeown SR; Worthington J; McKenna DJ
    Br J Cancer; 2016 Mar; 114(6):659-68. PubMed ID: 26954717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
    Ming L; Byrne NM; Camac SN; Mitchell CA; Ward C; Waugh DJ; McKeown SR; Worthington J
    Int J Cancer; 2013 Mar; 132(6):1323-32. PubMed ID: 22915157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.
    Browne G; Nesbitt H; Ming L; Stein GS; Lian JB; McKeown SR; Worthington J
    Br J Cancer; 2012 Nov; 107(10):1714-21. PubMed ID: 23073173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
    Salman H; Bergman M; Blumberger N; Djaldetti M; Bessler H
    Biomed Pharmacother; 2014 Feb; 68(1):21-4. PubMed ID: 24406295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
    Nesbitt H; Byrne NM; Williams SN; Ming L; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
    Clin Cancer Res; 2017 Apr; 23(7):1797-1808. PubMed ID: 27697998
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
    Bordini J; Morisi F; Elia AR; Santambrogio P; Pagani A; Cucchiara V; Ghia P; Bellone M; Briganti A; Camaschella C; Campanella A
    Clin Cancer Res; 2020 Dec; 26(23):6387-6398. PubMed ID: 32928793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
    Schayowitz A; Sabnis G; Goloubeva O; Njar VC; Brodie AM
    Br J Cancer; 2010 Sep; 103(7):1001-7. PubMed ID: 20842117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
    Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.